Aktuellt
SENASTE
Redeye provides a research update on Lipum following the Q4 report published by the company earlier today. Bolstered by the recent positive interim results from the ongoing phase I study with lead candidate SOL-116, Lipum announces that it is strengthening its finances through a SEK187m rights issue and is advancing the candidate into phase II trials.
LÄS MER
